Two Acts, One Geopolitical Moment
Long-acting Injectable Formulations
Electronic Logs - The next phase of execution maturity in pharma
Why Sustainable Biomanufacturing Must Start Earlier in The Process
Complex Journey from Innovation to Patient impact
EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
The Human Side of Pharma BD: Patience, Persistence, and Truly Understanding Client Needs
Client Relations Officer, PozeScaf Inc
Pragathi Yadhati is a Client Relations Officer at PozeScaf Inc and Chief Business Officer for healthtech startups ScribeJoy and NuMd Since she has advised pharma organisations on relationshipfocused business development and strategic partnerships fundraising and connecting companies with investors She served on the advisory board of IIT Jodhpur and brought a peoplecentered empathetic approach to...
Articles
Incipient Biopharmaceutical Claims of Milk Derived Exosomes
Exosomes are bilayer nanoextracellular vehicles EVs that areproduced by endocytosis in mammalian cells Under physiological conditions they are involved in intercellular communication viaproteins lipids and RNAs With a size distribution of nm exosomes have been identified in various biofluids
Research Insights
Relative expression of microRNAs, apoptosis, and ultrastructure anomalies induced by gold nanoparticles in Trachyderma hispida (Coleoptera: Tenebrionidae)
The extensive use of nanomaterials generates toxic effects on nontarget species and the ecosystem Although gold nanoparticles AuNPs are generally expected to be safe the recent study contains conflicting data regarding their cytotoxicity in the darkling beetles Trachyderma hispida
Case Studies
Bioavailability of Methadone After Sleeve Gastrectomy: A Planned Observational Case Study
Abstract Although there are no absolute contraindications to bariatric surgery most bariatric surgeons consider that patients with ongoing illicit drug use should not undergo such procedures The lack of clear recommendations within this field makes morbidly obese patients on opioidreplacement therapy a subgroup at risk for treatment refusal There is little
Techno Trends
Kura Oncology Introduces Breakthrough Therapy for Ziftomenib in Mutant Acute Myeloid Leukaemia
Kura Oncology has introduced ziftomenib a groundbreaking medication aimed at treating patients suffering from relapsedrefractory NPMmutant acute myeloid leukaemia
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
The Growing Role of Biocatalysis in Industrial Synthesis
Dr Reuben Carr has over 25 years of experience in developing proprietary biocatalytic processes for fine chemical and pharmaceutical manufacturing. He specialises in using directed evolution to engineer natural enzymes to carry out novel chemical reactions, enabling the synthesis of challenging molecular targets for clients and customers.
QSAR - Changing the Landscape of Antidiabetic Drug Discovery
Smriti Sharma Bhatia is an associate professor of chemistry at Miranda House, University of Delhi, India. Her academic and research interests include Computational chemistry and drug design. Currently, her research group is focused on the design of oral drug formulations for Type 2 diabetes mellitus. She is a popular science communicator.
Chemistry & AI
Dr. Ashok Kumar FRSC, President of the Centre for Research & Development at Ipca, earned his PhD from CDRI with Dr. Nityanand and post-doctoral experience from Sussex University with Nobel Laureate Prof. Cornforth. His interests include Chemical, Biotechnological & NDDR research and also integrating spirituality, philosophy, and common sense in his professional and personal life.
M&A, Partnerships & Ecosystem Models in Biopharma
Surbhi Gupta is an Industry Principal at Frost & Sullivan with extensive experience in global pharmaceutical and biotech market research and consulting. She leads the Biopharma Therapeutics program, focusing on next-generation modalities and precision medicine. Her work spans market analytics, forecasting, competitive benchmarking, and strategy support for biopharma clients globally.
Nanotechnology based Drug Delivery for Infectious Diseases
Dr. Vinod Kumar Rajana, Assistant Professor of Pharmaceutics, specializes in nanotechnology, bioassays, and infectious disease research. With expertise in nanoparticle synthesis, biotechnology, and drug delivery, his work integrates green chemistry with pharmaceutical innovation to develop sustainable, low-cost nanomaterials for topical antifungal and anticancer therapies, water purification, and biomedical applications.
press releasesRead more...
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
Shanghai Junshi Biosciences Co Ltd a leading innovationdriven biopharmaceutical company dedicated to the discovery development and commercialization of novel therapies announced that the supplemental new drug application for the companys product toripalimab injection subcutaneous injection
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
HUTCHMED China Limited today announces that the US Food and Drug Administration FDA has granted Orphan Drug Designation to sovleplenib for the treatment of primary immune thrombocytopenia ITP an autoimmune disorder that can lead to increased
Transpharmation Ltd. Announces Strategic Acquisition of OrganoTherapeutics SARL
Were delighted to announce the strategic acquisition of OrganoTherapeutics SARL a leader in patientderived organoid technologies that advance the discovery and development of novel therapies for neurodegenerativeCNS disorders
EVERSANA Expands Global Commercialization and AI-Powered HEOR Capabilities with Acquisition of U.K.-based Estima Scientific
EVERSANA a global provider of modern AIpowered commercial services for the biopharmaceutical industry today announced the acquisition of Estima Scientific an innovative Londonbased health economics and outcomes research HEOR technology and services company
Enhertu approved in the EU as adjuvant treatment for patients with residual disease after neoadjuvant treatment for HER2-positive early breast cancer
AstraZeneca and Daiichi Sankyos Enhertu trastuzumab deruxtecan has been approved in the European Union EU as a monotherapy for the adjuvant treatment of adult patients with resected HERpositive breast cancer who have residual invasive disease after neoadjuvant taxanebased and HERtargeted treatment
Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline
Teva Pharmaceuticals International GmbH a subsidiary of Teva Pharmaceutical Industries Ltd today announced that it has completed the acquisition of assets from BioXcel Therapeutics Inc including worldwide rights to BXCL BXCL is an investigational dexmedetomidine
EventsRead more...
28 - 30
Oct 2026BIOPLUS-INTERPHEX KOREA 2026
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
02 - 04
Nov 2026Cancer R&D 2026
Houston, TX, USA
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
03 - 04
Nov 2026PDA Aseptic Processing of Biopharma Conference
Sheraton Grand Incheon Hotel,...
04 - 05
Nov 2026Advanced Therapies USA
Hynes Convention Center, Bosto...
05 - 05
Nov 2026PDA Contamination Control Strategy Workshop
Sheraton Grand Incheon Hotel,...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
LATEST NEWSRead more...
Adalvo Acquires Romiplostim Biosimilar from Enzene
Adalvo has acquired a romiplostim biosimilar programme from Enzene expanding its portfolio of biosimilars and strengthening its presence in complex biological medicines The programme references Nplate romiplostim a medicine used to treat immune thrombocytopenia ITP in adults and children with chroni...
Twist Bioscience Launches Express Screening Antibodies for Faster Characterisation
Twist Bioscience has expanded its antibody production and characterisation portfolio with the launch of Twist Express Screening Antibodies a service designed to help researchers evaluate large numbers of antibody candidates more quickly The service uses a highthroughput cellfree production process t...
Astellas Enters into Agreement with Audax for Immuno-Oncology Candidate DAX-044
Astellas Pharma and Audax Biosciences have entered into an exclusive option and licence agreement for DAX an investigational antibodycytokine fusion being developed for cancer immunotherapy DAX is designed to deliver interleukin IL an immuneactivating protein more selectively to the tumour microenvi...
Sumitomo Pharma’s Enzomenib Receives Breakthrough Therapy Designation for Relapsed or Refractory KMT2A-Rearranged Acute Leukaemia
Sumitomo Pharma America has announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy designation to enzomenib DSP for treating patients with relapsed or refractory acute leukaemia carrying a KMTA gene rearrangement
Pfizer’s TALZENNA Plus XTANDI Approved for Earlier Treatment of Metastatic Prostate Cancer
Pfizer has received approval from the US Food and Drug Administration FDA to expand the use of TALZENNA talazoparib in combination with XTANDI enzalutamide for men with metastatic prostate cancer that is sensitive to hormone treatment and has specific homologous recombination repair HRR gene mutatio...
Okomera Signs Agreement with Servier for Cancer Research Technology
Okomera has signed a commercial agreement with Servier to support the development of new cancer treatments using its tumour miniaturisation technology More than of oncology drug candidates fail to reach the market making it important to identify promising treatments at an early stage Okomeras platf...
